Premium
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia: Marker analysis and significance
Author(s) -
Ifrah Norbert,
Boucheix Claude,
Marie JeanPierre,
Innes Jeanne,
Perrot JeanYves,
Rio Bernard,
Cadiou Monique,
Zittoun Robert
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861101)58:9<2018::aid-cncr2820580911>3.0.co;2-6
Subject(s) - calla , lymphocytosis , medicine , bone marrow , lymphoblast , acute lymphocytic leukemia , immunology , leukemia , persistence (discontinuity) , antigen , peripheral blood mononuclear cell , pathology , lymphoblastic leukemia , antibody , biology , biochemistry , geotechnical engineering , monoclonal antibody , engineering , in vitro , genetics , cell culture
In a series of 22 adult acute lymphoblastic leukemias expressing the common acute lymphoblastic leukemia antigen (cALLA +), eight had marrow lymphocytosis greater than 30% (43 ± 12%) with disappearance of marrow lymphoblasts and correction of bone marrow insufficiency at the end of the induction treatment. Four of these patients were studied for the cALL antigen, at this time and had persistance of this immunological marker (62 ± 15% of the mononuclear bone marrow cells). The evolution of these patients suggests that these patients were not in complete remission and emphasizes the usefulness of cALLA determination in cases with borderline excess of marrow lymphocytes.